stock · yahoo

Pfizer Inc.

PFE

$30.52
▲ 0.57 (1.9%)
polled

Below: live stock price for Pfizer Inc. (PFE), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Pfizer Inc. (PFE) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 75,000 people. Over the past year PFE traded between 23.62 and 30.67 USD. Trailing P/E sits near 40.16 on a market cap of about 173.95B USD. It currently yields 5.64% in dividends.

Day
+1.90%
+0.57
Week
+1.63%
+0.49
Month
+8.53%
+2.40
Year
+23.81%
+5.87
Prev close
$29.95
Volume (24h)
$1.13B
Market cap
$173.95B
Currency
USD

Score

42/ 100 · Weak

Coverage: 7/7
  • Value26
  • Quality54
  • Momentum49
  • Growth32
  • Risk68
  • Dividend35
  • Liquidity27

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 60%Pace +0.15% per bar
+5 bars+20 bars+60 bars+120 bars
+5 bars
30.7056
+0.61%
Bull32.4609
Bear29.0451
+20 bars
30.9634
+1.45%
Bull34.6049
Bear27.7052
+60 bars
31.0638
+1.78%
Bull37.6609
Bear25.6223
+120 bars
31.0675
+1.79%
Bull40.7931
Bear23.6606

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±1.25% per bar.

Interpretation

Composite signals look weak. Strength: risk profile with weakness: valuation. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

  • Value
    26/100

    Value looks fragile — driven by P/E (40.16).

    P/E:40.16P/B:2.04PEG:13.72
  • Quality
    54/100

    Quality looks mixed — driven by Gross margin (74.72%).

    ROE:5.01%ROA:5.78%Profit margin:6.80%Gross margin:74.72%
  • Momentum
    49/100

    Momentum looks mixed — driven by 52w change (23.76%).

    52w change:23.76%
  • Growth
    32/100

    Growth looks weak — driven by Revenue growth (2.60%).

    Revenue growth:2.60%
  • Risk
    68/100

    Risk looks solid — driven by Debt / equity (74.25).

    Beta:0.28Debt / equity:74.25Short interest:2.42%
  • Dividend
    35/100

    Dividend looks weak — driven by Payout ratio (226.32%).

    Dividend yield:5.64%Payout ratio:226.32%
  • Liquidity
    27/100

    Liquidity looks fragile — driven by Current ratio (1.27).

    Current ratio:1.27Quick ratio:0.85

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 251 days.

Position in range98%
23.62 low30.67 high

Where the price sits between the window low and high.

Volatility (annualised)
21.7%

Spread of returns. Higher means larger swings in both directions.

Max drawdown
-17.1%

Worst peak-to-trough fall inside the window.

Below period high
-0.5%

Current price against the highest point in the window.

Best day
+4.59%
Worst day
-3.41%
Up days
52%

Share of days that closed above the one before.

Current streak
2 up
Typical day swing
2.0%

Average high-to-low spread within a single day.

Volume vs average
-25%

Last 10 days against the whole window.

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above
31.9266 USD+4.61%
Fib +27.2% extension
Next level below
29.5797 USD-3.08%
Fib 23.6% retracement

Levels derived from: 30.67 high → 26.05 low · 60 bars

  • Resistance
    Fib +161.8% extension
    not reached
    38.1452 USD
    +24.98% from current
  • Resistance
    Fib +100% extension
    not reached
    35.29 USD
    +15.63% from current
  • Resistance
    Fib +61.8% extension
    not reached
    33.5252 USD
    +9.85% from current
  • Resistance
    Fib +27.2% extension
    not reached
    31.9266 USD
    +4.61% from current
  • Current
    30.52 USD
  • Support
    Fib 23.6% retracementNearest
    tested 5×
    29.5797 USD
    -3.08% from current
  • Support
    Fib 38.2% retracement
    tested 5×
    28.9052 USD
    -5.29% from current
  • Support
    Fib 50% midpoint
    tested 11×
    28.36 USD
    -7.08% from current
  • Support
    Fib 61.8% retracement
    tested 16×
    27.8148 USD
    -8.86% from current
  • Support
    Fib 78.6% retracement
    tested 2×
    27.0387 USD
    -11.41% from current
  • Support
    Fib −27.2% extension
    not reached
    24.7934 USD
    -18.76% from current
  • Support
    Fib −61.8% extension
    not reached
    23.1948 USD
    -24.00% from current
  • Support
    Fib −100% extension
    not reached
    21.43 USD
    -29.78% from current
How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high
$30.67
52w low
$23.62
52w change
23.76%
Day high
$30.67
Day low
$30.14
P/E (TTM)
40.16
Forward P/E
10.58
PEG
13.72
Price / Book
2.04
Beta (5Y)
0.28
Enterprise value
226.03B
EV / Revenue
3.55
EV / EBITDA
8.91
EPS (TTM)
$0.76
Forward EPS
$2.88
Dividend yield
5.64%
Dividend rate
$1.72
Payout ratio
226.32%
Revenue (TTM)
63.7B
EBITDA
25.38B
Free cash flow
12.49B
Total cash
11.7B
Total debt
63.48B
Debt / Equity
74.25
Current ratio
1.27
Quick ratio
0.85
Profit margin
6.80%
Gross margin
74.72%
Return on assets
5.78%
Return on equity
5.01%
Shares outstanding
5.7B
Float
5.69B
Sector: HealthcareIndustry: Drug Manufacturers - GeneralHQ: United StatesEmployees: 75Kwww.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Analyst & Risk

Consensus

Analysts' consensus via Yahoo Finance — not investment advice.

Analysts: positive
Mean rating2.50 / 5
Analysts26
Next earnings2026-11-03
Very positive: 1Positive: 8Neutral: 17Negative: 1Very negative: 1
Analyst price target
$29.26
Mean target · 26 analysts
-4.1%
mean target vs. price
Low $25.00Now $30.52High $36.00
Beta (vs S&P 500)
0.28
very stable
52-week change
23.76%
Short % of float
2.42%
Short ratio (days)
4.2
Debt / Equity
74.25
very high leverage
Current ratio
1.27
Quick ratio
0.85
ROE
5.01%
ROA
5.78%
PEG ratio
13.72
EV / Revenue
3.55
EV / EBITDA
8.91
Revenue growth
2.60%
EBITDA
25.38B
Free cash flow
12.49B
Total cash
11.7B
Total debt
63.48B
Insider holdings
0.10%
Institutional
69.11%

Recent rating changes

  • 2026-10-09JP MorganNeutral → Neutralmain
  • 2026-10-08Cantor FitzgeraldNeutral → Neutralmain
  • 2026-10-06ScotiabankSector Outperform → Sector Outperformmain
  • 2026-09-10HSBCHold → Holdmain
  • 2026-08-07GuggenheimBuy → Buymain
  • 2026-07-13BMO CapitalOutperform → Outperformmain
  • 2026-07-13GuggenheimBuy → Buymain
  • 2026-07-10B of A SecuritiesNeutral → Neutralmain

Recent news

Related

Other assets in this category.

Learn the terms

Live discussion

Sign in to join the discussion.

  • No comments yet. Be the first.